A composition with anti-wrinkle effects, its preparation method and application

Abstract

This invention belongs to the field of cosmetic technology and discloses a composition with anti-wrinkle effects, its preparation method, and its application. The composition of this invention comprises the following components: methylsilanol mannourate, acetyl hexapeptide-8, *Sparassis crippa* extract, and *Althaea rosa* flower extract. This composition, through the combination of methylsilanol mannourate, acetyl hexapeptide-8, *Sparassis crippa* extract, and *Althaea rosa* flower extract, exhibits a synergistic effect, enhancing its antioxidant capacity, maintaining cell stability, improving elasticity, smoothing wrinkles, and significantly delaying aging.

Description

Technical Field

[0001] This invention belongs to the field of cosmetic technology, and specifically relates to a composition with anti-wrinkle effects, its preparation method, and its application. Background Technology

[0002] As we age, aging is inevitable. Factors influencing aging include endogenous and exogenous factors, which manifest in the following ways: loss of skin elasticity, resulting in dry lines and fine lines; damage to the skin barrier, leading to facial redness; dull skin and enlarged pores; and sagging facial contours.

[0003] Currently, there are a variety of anti-aging skincare products on the market, but their functions are relatively limited and their effects are not ideal. Therefore, it is very necessary to develop an effective anti-wrinkle and anti-aging product. Summary of the Invention

[0004] The present invention aims to at least solve one of the technical problems existing in the prior art. To this end, the present invention provides a composition with anti-wrinkle effects, a method for preparing the composition, and its application. This composition achieves anti-wrinkle and anti-aging effects by stimulating cell renewal, collagen production, increasing elasticity, reducing wrinkles, and providing antioxidant benefits.

[0005] In a first aspect, the present invention provides a composition comprising the components: methylsilanol mannouronate, acetyl hexapeptide-8, *Hydrangea macrophylla* extract, and *Althaea humilis* flower extract.

[0006] Specifically, methylsilanol mannourate, as an organosilicon, combines silanol and mannourate to repair skin, reorganize connective tissue, stimulate cell growth, and generate new collagen.

[0007] Specifically, acetyl hexapeptide-8 mimics the N-terminal structure of SNAP-25 protein, competing with SNAP-25 for a position within the SNARE complex. This reduces the formation of the SNARE complex, thereby decreasing the release of acetylcholine (Ach) and achieving muscle relaxation. The SNARE complex refers to the process by which neuronal vesicle-associated membrane protein (VAMP) fused with SNAP-25 and the neuromuscular junction (NMJ) after stimulation of neuronal vesicles containing acetylcholine (Ach).

[0008] Specifically, Sprassis Crispa extract is a fungal extract rich in high-molecular-weight polysaccharides that has immunomodulatory, anti-inflammatory, antioxidant, and anti-radiation functions. In addition, Sprassis Crispa contains a large number of antioxidants, so the extract has a high antioxidant effect, which is beneficial for delaying aging.

[0009] Specifically, the main chemical components in the extract of hollyhock (ALTHAEA ROSEA) flowers are flavonoids and flavonoid glycosides; among them, flavonoid glycosides are excellent antioxidants that can help eliminate free radicals and delay aging.

[0010] The composition of this invention uses methylsilanol mannouronic acid ester, acetyl hexapeptide-8, Sparassis cripple extract, and Althaea rosea flower extract. These four ingredients work together to have a synergistic effect, which not only enhances the antioxidant capacity of the product, but also maintains cell stability, enhances elasticity, smooths wrinkles, and significantly delays aging.

[0011] In some embodiments of the present invention, the composition comprises, by weight parts: 0.01 to 5 parts of methylsilanol mannouronate, 0.1 to 20 parts of acetyl hexapeptide-8, 0.1 to 20 parts of *Hydrangea macrophylla* extract, and 0.05 to 3 parts of *Althaea humilis* flower extract.

[0012] In some embodiments of the present invention, the composition comprises, by weight parts: 0.1 to 5 parts of methylsilanol mannouronic acid ester, 0.1 to 15 parts of acetyl hexapeptide-8, 0.5 to 20 parts of *Hydrangea macrophylla* extract, and 0.1 to 3 parts of *Althaea humilis* flower extract.

[0013] In some embodiments of the present invention, the composition comprises, by weight parts: 0.1 to 3 parts of methylsilanol mannouronate, 0.25 to 12 parts of acetyl hexapeptide-8, 0.5 to 10 parts of *Hydrangea macrophylla* extract, and 0.1 to 1 part of *Althaea humilis* flower extract.

[0014] A second aspect of the present invention provides a method for preparing the composition described in the first aspect of the present invention, comprising the following steps:

[0015] The components are mixed to obtain a composition.

[0016] A third aspect of the invention provides the use of the composition described in the first aspect of the invention in the preparation of a product having at least one of the following effects: anti-wrinkle, anti-oxidation, anti-aging, and improved skin elasticity.

[0017] A fourth aspect of the present invention provides a cosmetic product comprising the composition described in the first aspect of the present invention.

[0018] In some embodiments of the present invention, the content of the composition in the cosmetic is 0.01 to 50 wt%, preferably 0.1 to 50 wt%; for example, it can be any value among 0.01 wt%, 0.1 wt%, 1 wt%, 5 wt%, 10 wt%, 20 wt%, 30 wt%, 40 wt%, and 50 wt%, or a range between two arbitrary values.

[0019] In some embodiments of the present invention, the cosmetic further includes at least one of a thickener, a moisturizer, a preservative, an emulsifier, and a skin moisturizer.

[0020] In some embodiments of the present invention, the thickener comprises, by weight parts, 0.2-0.5 parts of ammonium acryloyl dimethyl taurate / VP copolymer and 0.05-0.2 parts of xanthan gum; the moisturizer comprises 0.01-0.1 parts of sodium hyaluronate, 2-8 parts of glycerin, 1-8 parts of butylene glycol, and 0.5-1 parts of 1,2-hexanediol; the preservative comprises 0.01-0.5 parts of p-hydroxyacetophenone; the emulsifier comprises 1-4 parts of EMULGADE 165CN (glyceryl stearate, PEG-100 stearate), 0.5-2 parts of MONTANOV 6MB (cetearyl alcohol, cetearyl glucoside, glucose, water), and 0.2-1 parts of cetyl palmitate; and the emollient comprises shea butter (Butyrospermum). PARKII fruit oil 1-8 parts, pentaerythritol tetra(ethylhexanoate) ester 1-4 parts, glyceryl tri(ethylhexanoate) ester 1-8 parts, cetearyl alcohol 0.5-2 parts, behenol 0.2-2 parts, polydimethylsiloxane 2-10 parts, tocopheryl acetate 0.1-1 parts, polymethylsilsesquioxane 0.1-1 parts.

[0021] In some embodiments of the present invention, the cosmetic includes any one of facial cleanser, toner, serum, lotion, cream, mask, or foundation.

[0022] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0023] The composition provided by this invention is a combination of methylsilanol mannouronic acid ester, acetyl hexapeptide-8, Sparassis cripple extract and Althaea rosea flower extract. The four components work together to exert a synergistic effect, which can not only enhance its own antioxidant function, but also maintain cell stability, enhance elasticity, smooth wrinkles and reduce aging, thereby achieving the goal of significantly delaying aging. Detailed Implementation

[0024] To enable those skilled in the art to more clearly understand the technical solutions described in this invention, the following embodiments are provided for illustration. It should be noted that the following embodiments do not constitute a limitation on the scope of protection claimed by this invention.

[0025] Unless otherwise specified, the raw materials, reagents or devices used in this invention can be obtained from conventional commercial sources or by existing known methods.

[0026] Example 1

[0027] This example provides a composition comprising, by weight, 2 parts methylsilanol mannouronic acid ester, 8 parts acetyl hexapeptide-8, 5 parts SPARASSIS CRISPA extract, and 0.8 parts ALTHAEA ROSEA flower extract.

[0028] The composition in this example is prepared by mixing methylsilanol mannouronic acid ester, acetyl hexapeptide-8, SPARASSIS CRISPA extract and ALTHAEA ROSEA flower extract.

[0029] Example 2

[0030] This example provides a composition comprising, by weight, 0.01 parts of methylsilanol mannouronic acid ester, 0.1 parts of acetyl hexapeptide-8, 0.1 parts of SPARASSIS CRISPA extract, and 0.05 parts of Althaea rOSEA flower extract.

[0031] Example 3

[0032] This example provides a composition comprising, by weight, 5 parts of methylsilanol mannouronic acid ester, 20 parts of acetyl hexapeptide-8, 20 parts of SPARASSIS CRISPA extract, and 3 parts of ALTHAEA ROSEA flower extract.

[0033] Example 4

[0034] This example provides a composition comprising, by weight, 3 parts methylsilanol mannouronic acid ester, 8 parts acetyl hexapeptide-8, 10 parts SPARASSIS CRISPA extract, and 1 part Althaea rOSEA flower extract.

[0035] Example 5

[0036] This example provides a composition comprising, by weight, 2 parts methylsilanol mannouronic acid ester, 15 parts acetyl hexapeptide-8, 5 parts SPARASSIS CRISPA extract, and 0.8 parts ALTHAEA ROSEA flower extract.

[0037] The preparation methods of the compositions in Examples 2-5 are the same as those in Example 1.

[0038] Comparative Example 1

[0039] This example provides a composition with a formulation that is basically the same as that in Example 1, except that it does not contain ALTHAEA ROSEA flower extract.

[0040] Comparative Example 2

[0041] This example provides a composition with a formulation that is basically the same as that in Example 1, except that it does not contain Sparassis Crispa extract.

[0042] Comparative Example 3

[0043] This example provides a composition with a formulation that is basically the same as that in Example 1, except that it does not contain acetyl hexapeptide-8.

[0044] Comparative Example 4

[0045] This example provides a composition with a formulation that is basically the same as that in Example 1, except that it does not contain methylsilanol mannouronate.

[0046] Comparative Example 5

[0047] This example provides a composition with a formulation that is essentially the same as that in Example 1, except that it does not contain Sprasis Crispa extract or Althaea Rosea flower extract.

[0048] Comparative Example 6

[0049] This example provides a composition with a formulation that is essentially the same as that in Example 1, except that it does not contain acetyl hexapeptide-8 and marshmallow (ALTHAEA ROSEA) flower extract.

[0050] Comparative Example 7

[0051] This example provides a composition with a formulation that is essentially the same as that in Example 1, except that it does not contain acetyl hexapeptide-8 and Sparassis cripple extract.

[0052] Comparative Example 8

[0053] This example provides a composition with a formulation that is essentially the same as that in Example 1, except that it does not contain methylsilanol mannouronic acid ester and marshmallow (ALTHAEA ROSEA) flower extract.

[0054] Comparative Example 9

[0055] This example provides a composition with a formulation that is essentially the same as that in Example 1, except that it does not contain methylsilanol mannouronic acid ester and Sparasis cripple extract.

[0056] Comparative Example 10

[0057] This example provides a composition with a formulation that is essentially the same as that in Example 1, except that it does not contain methylsilanol mannouronate and acetyl hexapeptide-8.

[0058] Comparative Example 11

[0059] This example provides a composition with a formulation that is basically the same as that in Example 1, except that an equal amount of methylsilanol mannourate is replaced with sodium mannophosphate, which has similar effects.

[0060] Comparative Example 12

[0061] This example provides a composition with a formulation that is basically the same as that in Example 1, except that acetyl hexapeptide-8 is replaced in equal amounts with dipeptide diaminobutyryl benzylamide diacetate, which has similar effects.

[0062] Comparative Example 13

[0063] This example provides a composition with a formulation that is basically the same as that in Example 1, except that an equal amount of Sparassis Crispa extract is replaced with an Armillaria Matsutake extract, which has similar effects.

[0064] Comparative Example 14

[0065] This example provides a composition with a formulation that is basically the same as that in Example 1, except that the flower extract of Althaea oleracea is replaced in an equal amount with the root extract of Althaea officinalis, which has similar effects.

[0066] Composition efficacy test

[0067] Experimental Example 1: Antioxidant Efficacy Study—DPPH Free Radical Scavenging Experiment

[0068] Take 1g of the composition of Examples 1-5 and Comparative Examples 1-14, add 2mL of anhydrous ethanol, dissolve completely, then add 2mL of 60μmol / L DPPH solution and mix well. Let stand for 30min, zero with anhydrous ethanol, and measure the absorbance at 517nm as Ai; in the same way, take 2mL of anhydrous ethanol solvent + 2mL of DPPH solution, mix well and measure the absorbance as Ac; then take 1g of the composition matrix, dissolve it, add 2mL of anhydrous ethanol, add 2mL of anhydrous ethanol solvent, mix well and measure the absorbance as Aj.

[0069] Calculate its free radical scavenging rate using the following formula:

[0070] Clearance rate (%) = [1 - (Ai - Aj) / Ac] × 100%;

[0071] Where Aj is the contribution of the reaction sample itself to the absorbance; Ai is the absorbance value of the sample after DPPH treatment; and Ac is the absorption of DPPH itself at the measurement wavelength.

[0072] The DPPH free radical scavenging rate reflects its antioxidant capacity to a certain extent. The higher the scavenging rate, the better its antioxidant capacity and the better its anti-aging effect. Therefore, the anti-aging effect can be judged by studying the ability of the composition to scavenge DPPH free radicals.

[0073] The results are shown in Table 1 (each group of samples was measured in parallel 5 times, and the data are presented as average values).

[0074] Table 1

[0075]

[0076]

[0077] As shown in Table 1, the compositions of Examples 1-5 exhibit good DPPH scavenging effects. Higher DPPH scavenging rates indicate stronger antioxidant capacity and better anti-aging effects. The DPPH scavenging rates of Comparative Examples 1-14 are significantly lower than those of Examples 1-5. This indicates that the absence of one or more components in the compositions of this invention, or the substitution of components with other components, significantly reduces the DPPH scavenging effect. This demonstrates that the four components—methylsilanol mannouronate, acetyl hexapeptide-8, *Hydrangea macrophylla* extract, and *Althaea hollyhock* flower extract—are indispensable in the compositions of this invention.

[0078] Experiment 2: Inhibition of Metalloproteinase-1 (MMP-1)

[0079] Test method: Fibroblasts were seeded into 12-well cell culture plates, with each well containing 0.75 × 10⁶ cells. 5Cells were collected and starved in serum-free medium for 24 hours. The starved cells were washed with PBS and treated with UV light (40 mJ / cm²). 2 Then, the test sample was added to the cells twice within 48 hours. The concentration of MMP-1 isolated in the culture medium was measured using a kit (BIOTRAK RPN2610). The anti-aging ability was assessed by calculating the MMP-1 expression inhibition rate.

[0080] The calculation formula is as follows:

[0081] Inhibition rate = (AB) / A × 100%;

[0082] A: MMP-1 expression level after UV irradiation without adding test sample; B: MMP-1 expression level after UV irradiation with added test sample.

[0083] The results are shown in Table 2.

[0084] Table 2

[0085] Example 1 72.25 Example 2 70.11 Example 3 70.65 Example 4 71.64 Example 5 70.21 Comparative Example 1 45.23 Comparative Example 2 44.58 Comparative Example 3 45.33 Comparative Example 4 46.32 Comparative Example 5 30.87 Comparative Example 6 32.47 Comparative Example 7 30.12 Comparative Example 8 29.89 Comparative Example 9 30.68 Comparative Example 10 32.24 Comparative Example 11 44.86 Comparative Example 12 44.12 Comparative Example 13 43.88 Comparative Example 14 44.17

[0086] As shown in Table 2, the MMP-1 inhibition rates of the compositions in Examples 1-5 were significantly higher than those of the compositions in Comparative Examples 1-14, indicating that the anti-aging ability of the compositions in Examples 1-5 was superior to that of the compositions in Comparative Examples 1-14. This demonstrates that the absence of one or more components in the compositions of the present invention, or the replacement of components with other components, resulted in a significant decrease in the MMP-1 inhibition rate. This indicates that the methylsilanol mannouronate, acetyl hexapeptide-8, *Hydrangea macrophylla* extract, and *Althaea hollyhock* flower extract in the compositions of the present invention synergistically enhance each other's effects, and none of them can be omitted.

[0087] Application Examples 1-5

[0088] Application Examples 1-5 all provide a cream containing the composition of the present invention, the formulation of which is shown in Table 3.

[0089] Table 3

[0090]

[0091]

[0092] The preparation methods of the creams in Examples 1-5 are as follows:

[0093] (1) Deionized water, glycerol, butanediol, sodium hyaluronate, xanthan gum and ammonium acryloyldimethyl taurate / VP copolymer were stirred and dissolved in the weight ratio, heated to 80℃~85℃ and kept warm for 10min~15min to obtain phase A;

[0094] (2) The following ingredients were mixed and dissolved by stirring in the following weight ratio: avocado fruit oil, pentaerythritol tetra(ethylhexanoate), glyceryl tri(ethylhexanoate), cetearyl alcohol, behenyl alcohol, EMULGADE 165CN (glyceryl stearate, PEG-100 stearate), MONTANOV 6MB (cetearyl alcohol, cetearyl glucoside, glucose, water), and cetyl palmitate. The mixture was then heated to 80℃~85℃ to obtain phase B1.

[0095] (3) Polydimethylsiloxane, tocopheryl acetate and polymethylsilsesquioxane were mixed and dispersed evenly according to the weight ratio to obtain phase B2;

[0096] (4) Mix and dissolve 1,2-hexanediol and p-hydroxyacetophenone to obtain phase C;

[0097] (5) Add phases B1 and B2 to phase A, stir evenly, homogenize, and keep warm for 5 to 10 minutes; after cooling to 55℃ to 60℃, add phase C, stir evenly, and homogenize.

[0098] (6) After cooling to below 45°C, add the following composition by weight: methylsilanol mannouronic acid ester, acetyl hexapeptide-8, Sparassis crippa extract and Althaea rosea flower extract. Continue stirring until the temperature drops to below 38°C to obtain the cream.

[0099] Application Comparative Example 1

[0100] The difference between Comparative Example 1 and Application Example 1 is that Comparative Example 1 does not contain methylsilanol mannouronic acid ester, while the other components, dosages, and preparation methods are the same as in Application Example 1.

[0101] Application Comparative Example 2

[0102] The difference between Comparative Example 2 and Example 1 is that Comparative Example 2 does not contain acetyl hexapeptide-8, while the other components, amounts, and preparation methods are the same as in Example 1.

[0103] Application Comparative Example 3

[0104] The difference between Comparative Example 3 and Application Example 1 is that Comparative Example 3 does not contain Sparassiscrisppa extract, while the other components, amounts added, and preparation methods are the same as in Application Example 1.

[0105] Application Comparative Example 4

[0106] The difference between Comparative Example 4 and Application Example 1 is that Comparative Example 4 does not contain Althaea oleracea flower extract, while the other components, amounts added, and preparation methods are the same as in Application Example 1.

[0107] Application Comparative Example 5

[0108] The difference between Comparative Example 5 and Application Example 1 is that Comparative Example 5 does not contain acetyl hexapeptide-8, Hydrangea macrophylla extract and Althaea hollyhock extract, while the other components, amounts added and preparation methods are the same as in Application Example 1.

[0109] Application Comparative Example 6

[0110] The difference between Comparative Example 6 and Application Example 1 is that Comparative Example 6 does not contain methylsilanol mannouronic acid ester, Hydrangea macrophylla extract and Althaea hollyhock flower extract, while the other components, amounts added and preparation methods are the same as in Application Example 1.

[0111] Application Comparative Example 7

[0112] The difference between Comparative Example 7 and Application Example 1 is that Comparative Example 7 does not contain methylsilanol mannouronic acid ester, acetyl hexapeptide-8 and marshmallow flower extract, while the other components, amounts added and preparation methods are the same as in Application Example 1.

[0113] Application Comparative Example 8

[0114] The difference between Comparative Example 8 and Application Example 1 is that Comparative Example 8 does not contain methylsilanol mannouronic acid ester, acetyl hexapeptide-8 and Hydrangea spp. extract, while the other components, amounts added and preparation methods are the same as in Application Example 1.

[0115] Application Comparison Example 9

[0116] The difference between Comparative Example 9 and Application Example 1 is that Comparative Example 9 does not contain Hydrangea macrophylla extract and Althaea rosea extract, while the other components, amounts added, and preparation methods are the same as in Application Example 1.

[0117] Application Comparison Example 10

[0118] The difference between Comparative Example 10 and Example 1 is that Comparative Example 10 does not contain any composition, while the other components, amounts added, and preparation methods are the same as in Example 1.

[0119] Cream efficacy test

[0120] Experimental Example 3: Skin Elasticity Test

[0121] This test examines the skin elasticity of the creams used in Examples 1-5 and Comparative Examples 1-10.

[0122] A total of 150 eligible volunteers, aged 18 to 45 years, were recruited. The trial was designed as a randomized, double-blind, historically controlled study. Volunteers were randomly divided into 15 groups of 10 each, and tested with creams from Examples 1-5 and Comparative Examples 1-10, respectively. Volunteers applied the product to their face twice daily, morning and evening. Before application and on day 7 after application, under conditions of 21±1℃ and 50±10% humidity, elasticity (R² value) was measured after 20 minutes of cleansing the face.

[0123] Elasticity (R² value) change rate: This refers to the rate of change in skin elasticity after product use compared to before use. A positive value indicates an increase in the ratio of maximum skin stretch displacement, indicating better skin elasticity; a negative value indicates a decrease in the ratio of maximum skin stretch displacement, indicating poorer skin elasticity.

[0124] The test results are shown in Table 4.

[0125] Table 4

[0126]

[0127]

[0128] As shown in Table 4, the creams prepared in Application Examples 1-5 with the addition of the composition of the present invention can significantly improve skin elasticity and help delay aging. Creams prepared without the composition of the present invention, or lacking one or more components of the composition of the present invention (Application Examples 1-10), show a significantly reduced effect in improving skin elasticity. This indicates that the methylsilanol mannouronate, acetyl hexapeptide-8, Hydrangea macrophylla extract, and Althaea rosea extract in the composition of the present invention work synergistically and are indispensable.

[0129] Experimental Example 4: Anti-wrinkle test

[0130] This test examines the anti-wrinkle efficacy of the creams used in Examples 1-5 and Comparative Examples 1-10.

[0131] A total of 150 eligible volunteers, aged 18 to 45 years, were recruited. The trial was designed as a randomized, double-blind, historically controlled study. Volunteers were randomly divided into 15 groups of 10 each, and tested with creams from Examples 1-5 and Comparative Examples 1-10, respectively. Volunteers applied the product to their faces twice daily, morning and evening. On day 0, day 14 (D14), and day 28 (D28), under conditions of 21±1℃ and 50±10% humidity, volunteers cleansed their faces and waited 20 minutes before having their faces photographed using a VISIA7 camera. The number of wrinkles around the eyes and the total area of ​​wrinkles were measured.

[0132] Wrinkle count change rate: This refers to the rate of change in the number of wrinkles around the eyes after product use compared to before use. A positive value indicates an increase in the number of wrinkles around the eyes, meaning there are more wrinkles around the eyes; a negative value indicates a decrease in the number of wrinkles around the eyes, meaning there are fewer wrinkles around the eyes.

[0133] Change rate of total wrinkle area: This refers to the rate of change in the total area of ​​wrinkles around the eyes after product use compared to before use. A positive value indicates an increase in the total area of ​​wrinkles around the eyes, meaning more wrinkles are present; a negative value indicates a decrease in the total area of ​​wrinkles around the eyes, meaning fewer wrinkles are present.

[0134] Test Result Analysis:

[0135] (1) The results of the analysis of the number (strips) of wrinkles are shown in Table 5; (2) The results of the analysis of the total area of ​​wrinkles are shown in Table 6.

[0136] Table 5

[0137]

[0138]

[0139]

[0140] As can be seen from Table 5, the creams prepared in Application Examples 1-5 with the addition of the composition of the present invention can significantly reduce the increase in the number of wrinkles around the eyes. Creams prepared without the addition of the composition of the present invention, or lacking one or more components of the composition of the present invention (Application Examples 1-10), have a less than ideal effect in reducing the increase in the number of wrinkles around the eyes.

[0141] Table 6

[0142]

[0143]

[0144]

[0145] As can be seen from Table 6, the creams prepared in Application Examples 1-5 with the addition of the composition of the present invention can significantly reduce the total area of ​​wrinkles around the eyes. Creams prepared without the addition of the composition of the present invention, or lacking one or more components of the composition of the present invention (Application Examples 1-10), have a less than ideal effect in reducing the total area of ​​wrinkles around the eyes.

[0146] Based on the analysis of the test results of (1) and (2) in the above-mentioned test example 4, it can be concluded that the composition of the present invention, through the combination of four components, namely methylsilanol mannouronic acid ester, acetyl hexapeptide-8, SPARASSIS CRISPA extract and ALTHAEA ROSEA flower extract, has a synergistic effect and has excellent wrinkle-smoothing and anti-wrinkle effects.

[0147] The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the embodiments described. Those skilled in the art can make various equivalent modifications or substitutions without departing from the spirit of the present invention, and these equivalent modifications or substitutions are all included within the scope defined by the claims of this application.

Claims

1. A composition, characterized in that, The composition comprises, by weight parts, the following components: 0.01-5 parts of methylsilanol mannouronic acid ester, 0.1-20 parts of acetyl hexapeptide-8, 0.1-20 parts of *Hydrangea macrophylla* extract, and 0.05-3 parts of *Althaea humilis* flower extract.

2. The composition according to claim 1, characterized in that, The composition comprises, by weight parts, the following components: 0.1-5 parts of methylsilanol mannouronic acid ester, 0.1-15 parts of acetyl hexapeptide-8, 0.5-20 parts of *Hydrangea macrophylla* extract, and 0.1-3 parts of *Althaea humilis* flower extract.

3. The composition according to claim 2, characterized in that, The composition comprises, by weight parts, the following components: 0.1-3 parts of methylsilanol mannouronic acid ester, 0.25-12 parts of acetyl hexapeptide-8, 0.5-10 parts of *Hydrangea macrophylla* extract, and 0.1-1 parts of *Althaea humilis* flower extract.

4. A method for preparing the composition according to any one of claims 1 to 3, characterized in that, Includes the following steps: The components are mixed to obtain a composition.

5. The use of the composition according to any one of claims 1 to 3 in the preparation of cosmetics, characterized in that, The cosmetic product has at least one of the following effects: anti-wrinkle, antioxidant, and improved skin elasticity.

6. The use of the composition according to any one of claims 1 to 3 in the preparation of cosmetics, characterized in that, The cosmetic product has anti-aging effects.

7. A cosmetic product, characterized in that, Includes the composition according to any one of claims 1 to 3.

8. The cosmetic product according to claim 7, characterized in that, The content of the composition is 0.01~50wt%.

9. The cosmetic product according to claim 7, characterized in that, The cosmetics also include at least one of thickeners, moisturizers, preservatives, emulsifiers, and emollients.

10. The cosmetic product according to claim 7, characterized in that, The cosmetic product is selected from any one of the following: toner, serum, lotion, cream, mask, or foundation.

Images